In recent years, adenoviruses (Ads) have received considerable attention for use in gene therapy because of their relatively large cloning capacity, ease of genetic manipulation and growth, and their ability to transduce a wide range of tissue types containing both replicating and non-replicating cells. However, the initial enthusiasm over Ads has been tempered somewhat by their poor performance in both preclinical and clinical studies. Firstgeneration Ad vectors, which are rendered replicationdefective by deletion of E1, have proven generally to be inadequate for the long-term, stable transgene expression necessary for the correction of most genetic diseases. Many factors have been identified which can contribute to this poor performance, including: the use of foreign versus self transgenes; strong innate and inflammatory responses to the vector; acute and chronic toxicity; and generation of anti-Ad cytotoxic T-lymphocytes. It is likely that decay of transgene expression is due to a combination of several, or all, of these factors. However, expression from first-generation vectors has been shown to persist for long periods in immunodeficient animals suggesting that gene transfer to immune-privileged sites, such as the central nervous system (CNS), may have a greater potential for success.
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In this issue, three studies address Ad-mediated transgene delivery to the CNS. In the articles by Franklin et al. 1 and O'Leary and Charlton, 2 first-generation Ads are used to deliver a marker protein (␤-galactosidase, ␤-gal) to the white matter of rat spinal cords. Gene expression was relatively efficient, and ␤-gal could be detected in a variety of cell types including oligodendrocytes and astrocytes, in addition to ependymal cells and neurons of the grey matter. Unfortunately, in both studies Ad delivery was associated with substantial tissue damage, including evidence of demyelination, and necrosis. The degree of destruction appeared to correlate with the dose of Ad vector. Immunohistochemistry of the CNS tissue following Ad transduction revealed infiltrating cells expressing markers for molecules such as major histocompatibility complex I and II, complement receptor 3, leukocyte common antigen and OX-2, reflective of dendritic cells, and macrophage infiltration; however, many of these markers were also present following buffer treatment, demonstrating that mechanical perturbation of the tissue during delivery may have been responsible for at least some of the inflammatory response. None the less, the dose-dependent nature of Ad toxicity indicates that either gene expression from the Ad vector or some component of the virion was responsible for these effects. Interestingly, the Franklin et al. study demonstrated evidence of toxicity in athymic rats, suggesting that gene transfer to the CNS is limited by factors other than the adaptive immune response.
Lawrence et al. 3 describe the immunological effects of transgene delivery to the caudate nucleus of the brain of St. Kitts green monkeys using a first-generation Ad vector encoding ␤-gal. There appeared to be an inverse correlation between the degree of inflammation and number of transduced cells; however, administration of dexamethasone, an anti-inflammatory drug, did not increase the number of transduced cells, suggesting that either more potent anti-inflammatories are necessary for these applications or that toxicity may be independent of general inflammation. Multiple cell types were transduced in these experiments, including neurons, glia and ependymal cells. Gene delivery was associated with localized demyelination, necrosis and apoptosis, and infiltration by macrophage, and B-and T-lymphocytes, similar to the rodent studies. Interestingly, although all of the monkeys showed pre-existing antibodies to adenovirus, there was no correlation between transduction efficiency and antibody titer, suggesting that transduction of the primate CNS by Ad vectors is not limited by preexisting humoral immunity.
Taken together, the data presented in these studies indicate that although Ads are capable of transducing cells of the CNS at high efficiency, the toxicity and inflammation associated with Ad-mediated gene delivery makes first-generation Ad vectors inappropriate. Toxicity and inflammation may be due, at least in part, to lowlevel expression of viral proteins from the backbone of first-generation Ads, 4 which suggests that further modifications to these vectors are required before they can be effectively used for clinic applications to the CNS. "Second-generation" Ads, which contain additional deletions or mutations in the E2 or E4 region of the Ad genome, can further attenuate the expression of viral proteins, leading to prolonged vector persistence in some studies. 5 Recently, systems have been developed for the efficient generation of Ad vectors that are deleted of all Ad coding sequences, designated helper-dependent or "gutted" Ads. 6 These vectors retain the high transduction efficiency of first-generation Ads but do not lead to such deleterious responses as have been noted in the accompanying articles. 7 The toxicity and inflammation may be a direct result of the viral coat, in which case further deletion of the Ad genome will not have an impact on CNS damage. Modification of the virus genome to encode anti-inflammatory proteins may serve to enhance gene transfer by providing local inhibition and overcoming the limiting effects of the blood-brain barrier on systemic anti-inflammatory drugs. 8 Vectors based on herpes virus, which has a natural tropism for neurons, may be more attractive for CNS gene therapy. Recent advances in herpes vectorology have led to improvements which limit the toxicity observed in early studies.
